07:00 , Apr 21, 2014 |  BioCentury  |  Finance

European beachhead

European beachhead Epirus Biopharmaceuticals Inc. hopes its $36 million series B round and reverse merger with Zalicus Inc. (NASDAQ:ZLCS) will enable the biosimilars company to crack the European market. The combined public company will retain Epirus' name...
08:00 , Nov 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Riding the integrin wave in thrombosis

The use of platelet integrin a2bb3 inhibitors in thrombosis, while clinically very effective, is associated with a high risk of bleeding that has limited their use. Now, researchers at the University of Illinois at Chicago...
07:00 , Sep 17, 2012 |  BC Week In Review  |  Clinical News

Synavive: Development discontinued

Zalicus discontinued development of Synavive after the double-blind, international Phase IIb SYNERGY trial in 259 patients with moderate to severe RA showed that the compound missed the secondary endpoint of reducing DAS28-CRP scores from baseline...
07:00 , Sep 17, 2012 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/14 cls Amgen Inc. (NASDAQ:AMGN) Baird Christopher Raymond Downgrade Neutral (from outperform) ...
01:13 , Sep 11, 2012 |  BC Extra  |  Clinical News

Zalicus slides after dropping RA product

Zalicus Inc. (NASDAQ:ZLCS) fell $0.60 (43%) to $0.79 on Monday after discontinuing development of Synavive after it did not significantly reduce DAS28-CRP scores from baseline to week 12 vs. active comparator prednisolone in the Phase...
07:00 , May 7, 2012 |  BC Week In Review  |  Clinical News

Synavive: Completed Phase IIb enrollment

Zalicus completed enrollment of 292 patients with moderate to severe RA in the double-blind, placebo-controlled, international Phase IIb SYNERGY trial comparing once-daily Synavive vs. monotherapy with once-daily prednisolone, once-daily dipyridamole and once-daily prednisone. Zalicus Inc....
08:00 , Feb 23, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal damage Solute carrier family 29 nucleoside transporter member 1 (SLC29A1; ENT1) Studies in mice suggest...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

Synavive: Phase IIb started

Zalicus began the 12-week, double-blind, placebo-controlled, international Phase IIb SYNERGY trial to compare once-daily Synavive vs. monotherapy with once-daily prednisolone, once-daily dipyridamole and once-daily prednisone in about 250 patients with mild to moderate RA Zalicus...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

Aggrenox/Asasantin Retard dipyridamole regulatory update

The U.K.'s NICE issued final guidance recommending use of clopidogrel to prevent occlusive vascular events in patients with ischemic stroke, peripheral arterial disease (PAD) or multivascular disease, or in patients who have had a myocardial...
07:00 , Nov 1, 2010 |  BC Week In Review  |  Clinical News

Plavix clopidogrel regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending wider use of clopidogrel due to the availability of cheaper generic versions of the antiplatelet drug in the U.K. The agency recommends use of the...